At Skåne University hospital we have a long history of treating patients with HSCT for a variety of diseases such as leukemia, myeloma, lymphoma, and other blood and immune system diseases that affect the bone marrow.
HSCT is performed with cells from a donor, either a human leukocyte antigen (HLA) identical sibling or reasonably HLA-matched unrelated donor, for all current indications, malignant and non-malignant. Since 1998, we have performed haploidentical HSCT, where a half HLA-matched relative serves as a donor. Due to this, transplantation can be performed on virtual all eligible patients. Our stem cell programme is internationally accredited (JACIE) .
The department is closely linked to Lund University, integrating the latest research findings in the clinical work. We have well-established national and international collaboration, which means that our oncologists/ hematologists take part in working groups and protocols. Based on the successful model of work, senior consultants at the department have provided long-term support and training for establishment of new clinics abroad as well as in development of multi-unit monitoring systems.
We are also very proud to be able to function as the operational center for all Icelandic allogeneic HSCT patients since 2020.